Report
Ken Cheng ...
  • Kevin Augustyn
  • Mark Hirshorn
  • Stephanie Mah

PACE Sector Expected to Remain Stable

Over the past 18 months, the property assessed clean energy (PACE) sector has remained resilient despite the economic turmoil triggered by the ongoing coronavirus pandemic. Both commercial PACE (C-PACE) and residential PACE (R-PACE) transactions have continued to perform as expected, with delinquency rates remaining low and no realized principal losses to date. DBRS Morningstar expects the PACE sector to remain stable for the remainder of the year.

• Although some C-PACE portfolios have exposure to hotel and retail properties, we have not witnessed any credit deterioration in securitized C-PACE transactions owing to a number of inherent features and factors: the seniority of amortizing C-PACE assessments, the liens on real estate properties, and the underlying low loan-to-value ratios (LTVs) have all contributed to the positive performance across the sector.
• On the R-PACE side, borrowers have benefited from the various unprecedented federal stimulus packages in the form of one-time payments and additional unemployment benefits.
Provider
DBRS Morningstar
DBRS Morningstar

DBRS Morningstar is a global credit ratings business with 700 employees in eight offices globally. DBRS and Morningstar Credit Ratings are committed to empowering investor success, serving the market through leading-edge technology and raising the bar for the industry.

Together, we are the world’s fourth largest credit ratings agency and a market leader in Canada, the U.S. and Europe in multiple asset classes. We rate more than 2,600 issuers and 54,000 securities worldwide and are driven to bring more clarity, diversity and responsiveness to the ratings process. Our approach and size provide the agility to respond to customers’ needs, while being large enough to provide the necessary expertise and resources. For more details visit us at dbrs.com.

Analysts
Ken Cheng

Kevin Augustyn

Mark Hirshorn

Stephanie Mah

ResearchPool Subscriptions

Get the most out of your insights

Get in touch